David C. Seldin, M.D., Ph.D.

Chief, Section of Hematology-Oncology

Education:

BA (Physics) 1978, Harvard College, Cambridge MA
MD, PhD (Immunology), 1986, Harvard Medical School and M.I.T. Program in Health, Science, and Technology, Boston MA
Internship and Residency in Internal Medicine, 1986-1988, Brigham & Women’s Hospital, Boston MA
Fellowship in Hematology and Medical Oncology, 1988-1991, Brigham & Women’s Hospital and Dana Farber Cancer Institute, Boston MA
Post-Doctoral Fellow in Genetics, 1989-1994, Leder Lab, Harvard Medical School, Boston MA

General field of research:

Hematology, oncology, amyloidosis, stem cell transplantation, cancer research

Affiliations other than medicine:

Amyloidosis Treatment and Research Program
Cancer Center
Women’s Health Interdisciplinary Research Center
BU Clinical and Translational Sciences Institute
Molecular Medicine Graduate Program
Hematology Training Program
Immunology Training Program

Contact information:

Office
Heme-Onc Section, EBRC4
Phone: (617)-638 7027

Lab
Amyloid Program, K5
Phone: (617)-638 7022
Fax: (617)-638 7530

dseldin@bu.edu

Other research websites:

Seldin Lab Research Page
http://www.bumc.bu.edu/hematology/research-activities/david-c-seldin-md-phd/

Amyloid Treatment & Research Program
http://www.bu.edu/amyloid/

BU Clinical and Translational Sciences Institute
http://ctsi.bu.edu/

Heme-Onc Section Academic Website
http://www.bumc.bu.edu/hematology/

Heme-Onc Section Clinical Website
http://www.bmc.org/hematologyoncology.htm

Keywords:

Amyloidosis; breast cancer; casein kinase II; wnt signaling; stem cell transplantation

Summary of research interest:

Dr. Seldin is the Chief of the Section of Hematology-Oncology in the Department of Medicine, and he also directs the multidisciplinary Amyloidosis Treatment and Research Program at BUSM and BMC. He is a Professor of Medicine and of Microbiology, a member of the Cancer Center Executive Committee, a member and former director o! f the graduate program in Molecular Medicine, a member of the Immunology and Hematology Training Programs, and of the Women’s Health InterdisciplinaryResearch Center. He is also the Director of Translational Technologies and Resources for the BU Clinical and Translational Sciences Institute. He is co-director of the Cancer Biology and Genetics course, and of the Molecules to Molecular Therapeutics course. His research interests include amyloidosis and diseases of protein misfolding, and kinases and cancer, particularly protein kinase CK2 and its role in breast cancer, lymphoma, and development.

Recent publications:

Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC. 2007.  Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation, Blood; 110(10):3561-3. PMID: 17673601

Belguise K, Guo S, Yang S, Rogers AE, Seldin DC, Sherr DH, and Sonenshein GE. 2007.  Green Tea
Polyphenols Reverse Cooperation between c-Rel and CK2 that Induces the Aryl Hydrocarbon Receptor, Slug and an Invasive Phenotype, Cancer Research; 67(24):11742-5. PMID: 18089804

Lou DY, Dominguez I, Toselli P, Landesman-Bollag E, O’Brien C, and Seldin DC. 2008.  The Alpha Catalytic Subunit Of Protein Kinase CK2 Is Required For Mouse Embryonic Development, Mol Cell Biol.; 28(1):131-9. PMID: 17954558

Lavatelli F, Perlman DH, Spencer B, Prokaeva T, McComb ME, Théberge R, Connors LH, Bellotti V, Seldin DC, Merlini G, Skinner M, Costello CE. 2008.  Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. Mol Cell Proteomics;7(8):1570-83. PMID: 18474516

Biolo A, Ramamurthy S, Connors LH, O’Hara CJ, Meier-Ewert HK, Soo Hoo PT, Sawyer DB, Seldin
DC, and Sam F.  2008.  Matrix Metalloproteinases and Their Tissue Inhibitors in Cardiac Amyloidosis:
Relationship to Structural, Functional Myocardial Changes and to Light Chain Amyloid Deposition. Circ
Heart Fail; 1: 249 – 257. PMID: 19808299

Bodi K, Prokaeva T, Spencer B, Eberhard M, Connors LH, Seldin DC.  2009.  AL-Base: a visual platform analysis tool for the study of amyloidogenic immunoglobulin light chain sequences. Amyloid; 16(1):1-8. PMID: 19291508

Wu H, Symes K, Seldin DC, Dominguez I.  2009.  Threonine 393 of beta-catenin regulates interaction with Axin. J Cell Biochem; 108(1):52-63. PMID: 19565571

Connors LH, Prokaeva T, Lim A, Théberge R, Falk RH, Doros G, Berg A, Costello CE, O’Hara C, Seldin DC, Skinner M.  2009.  Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J.; 158(4):607-14. PMID: 19781421